UBS Upgrades Cytokinetics to 'Buy' with $115 Price Target

On June 29, 2026, UBS analyst Ashwani Verma upgraded Cytokinetics, Incorporated (NasdaqGS: CYTK) to a 'buy' rating, setting a price target of $115. This marks a positive outlook for the biotech company, which focuses on muscle activators and inhibitors.

Other Institutional Activity in Cytokinetics

Several major institutional investors have been active in Cytokinetics recently. T. Rowe Price Investment Management trimmed its holdings by 192,532 shares, leaving it with 17,523,840 shares valued at about $1.15 billion, a 1.1% decrease. BlackRock, Inc. added 152,888 shares, increasing its position by 0.9% to 16,548,011 shares worth approximately $1.09 billion. FMR LLC reduced its stake significantly by 2,084,612 shares, a 16.3% decrease, ending with 10,723,140 shares valued at $706.76 million. Wellington Management Group LLP slightly increased its holdings by 72,426 shares, up 0.9%, for a total of 8,009,489 shares worth $527.91 million. Vanguard Portfolio Management LLC opened a new position with 5,843,782 shares valued at $385.16 million.

Cytokinetics, Incorporated Stock Up 20.1%

Shares of Cytokinetics traded near $82.19 on Monday. The company has a market cap of approximately $11.16 billion and a beta of 0.435, indicating lower volatility compared to the market. Cytokinetics has seen a 52-week high of $84.55 and a low of $32.66. The stock's 50-day moving average is $72.43, while the 200-day moving average is $64.45. The company maintains a strong liquidity position with a current ratio of 4.214 and a quick ratio of 4.144.

Recent Earnings

Cytokinetics reported $105.82 million in revenue, representing a growth of 11.3%. However, the company is not currently profitable, with a negative EPS of $6.85 and no meaningful net margin. Investors will be watching for the next earnings report, scheduled for August 6, 2026.

Insider Buying and Selling at Cytokinetics, Incorporated

Recent insider transactions include several by EVP of Research & Development, Malik Fady Ibrahim. On June 23, 2026, he sold 3,500 shares at an average price of $79.51 in a planned sale and bought 3,500 shares at $7.80 in an unplanned purchase. Earlier, on June 9, he sold 3,500 shares at $67.98 in a planned sale and bought 3,500 shares at $7.80 in another unplanned purchase. Additionally, President and CEO Robert Blum sold 7,500 shares at $70.46 on June 15 in a planned transaction.

Analysts Set New Price Targets

UBS's upgrade to a 'buy' rating with a $115 target on June 29 was followed by several other analyst actions. On June 24, Mizuho maintained its 'buy' rating with a $118 target. Citigroup initiated coverage with a 'buy' rating and a $99 target on May 19. Other firms like JP Morgan, HC Wainwright & Co., Wells Fargo, Stifel, and Morgan Stanley have maintained their 'buy' ratings with price targets ranging from $97 to $140. The consensus among 20 analysts is a 'buy' rating, with a mean target price of $105.60.

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company based in South San Francisco, California. It focuses on developing novel muscle activators and inhibitors for treating debilitating diseases. The company markets MYQORZO, a cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Cytokinetics is also working on other treatments like Aficamten and omecamtiv mecarbil for heart failure, and Ulacamten and CK-089 in early-phase trials. Led by CEO Robert I. Blum, Cytokinetics employs 673 people.

Bottom Line

UBS's upgrade of Cytokinetics to a 'buy' rating with a $115 price target reflects optimism about the company's potential in the biotechnology sector. With a strong liquidity position and ongoing development of promising treatments, Cytokinetics remains a company to watch. As always, remember that analyst ratings and 13F filings are backward-looking and may not reflect current conditions.